Drug Profile
Research programme: renin inhibitors 800 series - Speedel/Locus
Alternative Names: SPP 800Latest Information Update: 11 Mar 2009
Price :
$50
*
At a glance
- Originator Locus Pharmaceuticals; Speedel Experimenta
- Developer Novartis
- Class
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 28 Jan 2009 Discontinued - Preclinical for Hypertension in Switzerland (unspecified route)
- 09 Jul 2008 Speedel has been acquired by Novartis
- 05 Apr 2006 This programme is still in active development - (BIO-Europe-2005)